Stock Sale By Pfizer’s Bourla Exemplifies Possible Need For Reform, US Senators Tell SEC
Executive Summary
Sens. Brown, Warren and Van Hollen portray biopharma as the poster child of potential corporate abuses of so-called 10b5-1 plans, which are designed to allow executives to sell stock while avoiding insider trading.